Journal: Cell

Article Title: B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV

doi: 10.1016/j.cell.2021.04.032

Figure Lengend Snippet:

Article Snippet: HRP Conjugated Goat anti-Human Lambda Light Chain Antibody , Bio-Rad , Cat#STAR129P; RRID: AB_1102721.

Techniques: Virus, Recombinant, Staining, Plasmid Preparation, Expressing, Modification, Luciferase, Cell Culture, Lysis, Reporter Gene Assay, Enzyme-linked Immunosorbent Assay, Electron Microscopy, Cloning, Software, Chromatography, Spectrophotometry

Journal: Cell chemical biology

Article Title: Quantitative Interactome Proteomics Reveals a Molecular Basis for ATF6-Dependent Regulation of a Destabilized Amyloidogenic Protein

doi: 10.1016/j.chembiol.2019.04.001

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Briefly, wells were coated overnight at 37 °C with sheep polyclonal free λ LC antibody (Bethyl Laboratories, A80-127A) at a 1:500 dilution in 50 mM sodium carbonate (pH 9.6).

Techniques: Recombinant, Sequencing, Modification, Purification, Labeling, Expressing, Plasmid Preparation, Clone Assay, Software

Journal: Discover Oncology

Article Title: IGLC1 is an independent prognostic marker and potent therapeutic target in osteosarcoma

doi: 10.1007/s12672-025-02653-6

Figure Lengend Snippet: IGLC1 expression in osteosarcoma and non-neoplastic bone specimens. A Representative immunohistochemical staining of IGLC1 in osteosarcoma tissues and non-neoplastic bone specimens. Scale bars: 100 μm (top) and 50 μm (bottom). B Immunohistochemical scores of IGLC1 expression were significantly higher in osteosarcoma tissues compared to non-neoplastic bone specimens; **** P < 0.001

Article Snippet: The membranes were then incubated with primary antibodies against IGLC1 (Cat. No. #20,758–1-AP, 1:500 dilution, Proteintech Group, Wuhan, China) and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Cat. No. #380,626; 1:5000; Zenbio, Chengdu, China) overnight at 4 °C and HRP-conjugated secondary antibodies (Cat. No. 550064; 1:10,000; Zenbio, Chengdu, China) for 1 h. The membranes were washed 3 times with 1 × TBST (Cat. No. BL315B, Biosharp, Hefei, China) and immersed in enhanced chemiluminescence solution (Cat. No. BL520A, Biosharp, Hefei, China).

Techniques: Expressing, Immunohistochemical staining, Staining

Journal: Discover Oncology

Article Title: IGLC1 is an independent prognostic marker and potent therapeutic target in osteosarcoma

doi: 10.1007/s12672-025-02653-6

Figure Lengend Snippet: Kaplan–Meier survival analysis of overall survival in osteosarcoma patients. A Patients with high IGLC1 expression had significantly poorer overall survival compared to those with low expression (HR = 3.028, 95% CI = 1.687–5.437, P < 0.001). B Patients with high LDH levels exhibited significantly poorer overall survival compared to those with normal LDH levels (HR = 2.793, 95% CI = 1.630–4.789, P < 0.001)

Article Snippet: The membranes were then incubated with primary antibodies against IGLC1 (Cat. No. #20,758–1-AP, 1:500 dilution, Proteintech Group, Wuhan, China) and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Cat. No. #380,626; 1:5000; Zenbio, Chengdu, China) overnight at 4 °C and HRP-conjugated secondary antibodies (Cat. No. 550064; 1:10,000; Zenbio, Chengdu, China) for 1 h. The membranes were washed 3 times with 1 × TBST (Cat. No. BL315B, Biosharp, Hefei, China) and immersed in enhanced chemiluminescence solution (Cat. No. BL520A, Biosharp, Hefei, China).

Techniques: Expressing

Journal: Discover Oncology

Article Title: IGLC1 is an independent prognostic marker and potent therapeutic target in osteosarcoma

doi: 10.1007/s12672-025-02653-6

Figure Lengend Snippet: Functional effects of IGLC1 knockdown in osteosarcoma cells. A IGLC1 knockdown efficiency was validated by real-time PCR and western blot assays. B CCK-8 assay showed a significant reduction in cell proliferation following IGLC1 knockdown. C Colony formation assay revealed that IGLC1 knockdown significantly impaired the clonogenic ability of osteosarcoma cells. D , E Transwell migration and wound healing assays demonstrated that IGLC1 knockdown markedly reduced cell migration ability. F Transwell invasion assay showed that IGLC1 knockdown significantly decreased the invasive potential of osteosarcoma cells. Note : *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Usually the blots were cut prior to hybridisation with antibodies

Article Snippet: The membranes were then incubated with primary antibodies against IGLC1 (Cat. No. #20,758–1-AP, 1:500 dilution, Proteintech Group, Wuhan, China) and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Cat. No. #380,626; 1:5000; Zenbio, Chengdu, China) overnight at 4 °C and HRP-conjugated secondary antibodies (Cat. No. 550064; 1:10,000; Zenbio, Chengdu, China) for 1 h. The membranes were washed 3 times with 1 × TBST (Cat. No. BL315B, Biosharp, Hefei, China) and immersed in enhanced chemiluminescence solution (Cat. No. BL520A, Biosharp, Hefei, China).

Techniques: Functional Assay, Knockdown, Real-time Polymerase Chain Reaction, Western Blot, CCK-8 Assay, Colony Assay, Migration, Transwell Invasion Assay, Hybridization